Name | Number of supported studies | Average coverage | |
---|---|---|---|
T cell | 7 studies | 29% ± 10% | |
B cell | 6 studies | 25% ± 4% | |
transit amplifying cell | 6 studies | 38% ± 12% | |
plasmablast | 5 studies | 27% ± 14% | |
epithelial cell | 4 studies | 28% ± 15% | |
pro-B cell | 4 studies | 29% ± 8% | |
erythrocyte | 4 studies | 33% ± 14% | |
natural killer cell | 4 studies | 26% ± 6% | |
effector CD8-positive, alpha-beta T cell | 4 studies | 25% ± 7% | |
CD4-positive, alpha-beta T cell | 4 studies | 42% ± 15% | |
CD8-positive, alpha-beta T cell | 4 studies | 34% ± 12% | |
conventional dendritic cell | 3 studies | 18% ± 2% | |
macrophage | 3 studies | 20% ± 2% | |
endothelial cell | 3 studies | 18% ± 2% | |
abnormal cell | 3 studies | 27% ± 9% | |
plasma cell | 3 studies | 26% ± 4% | |
hematopoietic precursor cell | 3 studies | 22% ± 5% |
Insufficient scRNA-seq data for expression of TOP2A at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 95% | 6362.09 | 1723 / 1809 | 87% | 65.51 | 411 / 472 |
lung | 60% | 589.19 | 344 / 578 | 91% | 89.90 | 1053 / 1155 |
intestine | 54% | 1043.21 | 526 / 966 | 95% | 99.96 | 502 / 527 |
stomach | 50% | 688.30 | 178 / 359 | 97% | 104.90 | 277 / 286 |
esophagus | 44% | 1416.57 | 629 / 1445 | 100% | 193.68 | 183 / 183 |
breast | 23% | 125.68 | 104 / 459 | 92% | 101.02 | 1026 / 1118 |
bladder | 19% | 141.14 | 4 / 21 | 94% | 96.01 | 476 / 504 |
uterus | 13% | 101.05 | 22 / 170 | 97% | 130.99 | 447 / 459 |
tonsil | 0% | 0 | 0 / 0 | 100% | 147.75 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 29.29 | 1 / 1 |
ovary | 8% | 128.63 | 14 / 180 | 90% | 49.64 | 386 / 430 |
lymph node | 0% | 0 | 0 / 0 | 97% | 93.15 | 28 / 29 |
spleen | 94% | 1193.95 | 226 / 241 | 0% | 0 | 0 / 0 |
pancreas | 6% | 35.21 | 19 / 328 | 70% | 36.68 | 124 / 178 |
liver | 15% | 176.40 | 33 / 226 | 47% | 21.27 | 190 / 406 |
adrenal gland | 45% | 304.80 | 117 / 258 | 13% | 6.55 | 30 / 230 |
peripheral blood | 54% | 5271.98 | 506 / 929 | 0% | 0 | 0 / 0 |
brain | 1% | 7.67 | 32 / 2642 | 49% | 36.57 | 347 / 705 |
prostate | 18% | 105.66 | 43 / 245 | 19% | 6.35 | 95 / 502 |
thymus | 18% | 95.22 | 115 / 653 | 19% | 21.42 | 113 / 605 |
kidney | 17% | 155.57 | 15 / 89 | 17% | 7.13 | 153 / 901 |
adipose | 26% | 177.73 | 311 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 14% | 73.80 | 187 / 1335 | 0% | 0 | 0 / 0 |
heart | 8% | 52.33 | 73 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 8% | 1.67 | 6 / 80 |
muscle | 1% | 3.21 | 7 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0002244 | Biological process | hematopoietic progenitor cell differentiation |
GO_0007059 | Biological process | chromosome segregation |
GO_0006974 | Biological process | DNA damage response |
GO_0007143 | Biological process | female meiotic nuclear division |
GO_0030263 | Biological process | apoptotic chromosome condensation |
GO_0042752 | Biological process | regulation of circadian rhythm |
GO_1905463 | Biological process | negative regulation of DNA duplex unwinding |
GO_0006265 | Biological process | DNA topological change |
GO_0000712 | Biological process | resolution of meiotic recombination intermediates |
GO_0040016 | Biological process | embryonic cleavage |
GO_0000819 | Biological process | sister chromatid segregation |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0006266 | Biological process | DNA ligation |
GO_0048511 | Biological process | rhythmic process |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0045870 | Biological process | positive regulation of single stranded viral RNA replication via double stranded DNA intermediate |
GO_0000775 | Cellular component | chromosome, centromeric region |
GO_0005730 | Cellular component | nucleolus |
GO_0000228 | Cellular component | nuclear chromosome |
GO_0009330 | Cellular component | DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005814 | Cellular component | centriole |
GO_0005737 | Cellular component | cytoplasm |
GO_0000793 | Cellular component | condensed chromosome |
GO_0001673 | Cellular component | male germ cell nucleus |
GO_1990904 | Cellular component | ribonucleoprotein complex |
GO_0005634 | Cellular component | nucleus |
GO_0005080 | Molecular function | protein kinase C binding |
GO_0003677 | Molecular function | DNA binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0008301 | Molecular function | DNA binding, bending |
GO_0003682 | Molecular function | chromatin binding |
GO_0003918 | Molecular function | DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity |
GO_0000287 | Molecular function | magnesium ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0008094 | Molecular function | ATP-dependent activity, acting on DNA |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
Gene name | TOP2A |
Protein name | DNA topoisomerase 2-alpha (EC 5.6.2.2) (DNA topoisomerase II, alpha isozyme) DNA topoisomerase 2 (EC 5.6.2.2) DNA topoisomerase II alpha |
Synonyms | TOP2 |
Description | FUNCTION: Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand . May play a role in regulating the period length of BMAL1 transcriptional oscillation (By similarity). . FUNCTION: Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand. . |
Accessions | ENST00000581055.1 ENST00000423485.6 [P11388-1] J3KTB7 A0A4D6UXC9 J3QR57 ENST00000577541.1 P11388 |